- Sales -6%, adj. EBITA +5% vs cons in Q3 - Strong performance in product companies behind solid mar...
- Net sales SEK 512m, -6% vs ABGSCe and -5% vs Factset cons.
- Mixed Q3, but with signs of improvements - We revise EBITDA down by 1.
- Minor estimate revisions - Decline in utilisation appears to have stopped - '25e EV/EBITA of 8x H2...
- Both segments performed above our expectations in Q3 - EBIT up 2-1%, market to remain weak in H1'2...
- Technical production disruptions in the hot cell - Scandpower showing positive signs - We lower '2...
- Q3 earnings miss reduces '24e EBIT, but order beat raises '25e - Market activity remains high and ...
- Q3 production much as expected - All share offer likely to be accepted - P/NAV of 1.
MoveByBike AB (”MoveByBike eller ”Koncernen”) fortsätter att utöka reklamintäkter genom ett nytt sam...
Det svenska bioteknikbolaget Aptahem AB (publ) (”Aptahem” eller ”Bolaget”) utvecklar RNA-baserade lä...
Redeye increases its fair value range following a closer look at the report.
Cereno Scientific recently held a capital markets day (CMD), providing greater insight on its develo...
Redeye shares its initial comments on Heliospectra's Q3 results, noting that sales and cost base fig...
Redeye sees a weak Q3 negatively impacted by a soft market and postponed projects.
Redeye believes Sdiptech's Q3 report was weaker than expected, with continued positive organic sales...
Redeye notes AVTECH's report aligned with estimates and the pre-announced figures.
Acconeer's net sales grew 74% y/y but deviated 16% from our estimate.
Redeye comments on Doro´s third quarter of the year.
Svedbergs Group posted a soft set of Q3 2024 numbers, with sales coming in 4% below our estimates (n...
Redeye retains its positive view on Lagercrantz following a Q2 report in-line with our estimates.
